Repros Therapeutics files for $40.575 million stock shelf

By Jennifer Chiou

New York, Sept. 5 - Repros Therapeutics Inc. registered to sell up to $40.575 million of stock in an S-3 registration with the Securities and Exchange Commission.

The company plans to issue 5 million shares at a proposed maximum price of $8.115 per share.

Proceeds will go towards general corporate purposes, including clinical trials for the company's lead products, Proellex, for the treatment of uterine fibroids and endometriosis, and Androxal, for the treatment of testosterone deficiency in men.

The Woodlands, Texas-based Repros is a pharmaceutical company focused on developing products that address male and female reproductive systems.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.